

A comparison of two doses of tamoxifen (Nolvadex*) in postmenopausal women with advanced breast cancer: 10 mg bd versus 20 mg bd

D.G. Bratherton¹, C.H. Brown¹, R. Buchanan², V. Hall², E.M. Kingsley Pillers¹, T.K. Wheeler¹ & C.J. Williams²

¹Addenbrooke's Hospital, Hills Road, Cambridge, CB2 2QQ; ²Royal South Hants Hospital, Fanshawe Street, Southampton SO9 4PE UK.

Summary In a comparative double-blind trial involving 263 postmenopausal women with advanced breast cancer treated with tamoxifen, the mean objective tumour response rate and duration was 32% and 15 months respectively. No significant difference was found in clinical response and adverse effects between those randomised to 10 mg and those to 20 mg twice daily. Although the mean serum concentration of tamoxifen in the 20 mg bd group was significantly higher no correlation between serum level and clinical benefit was demonstrated.

Tamoxifen (Nolvadex*) is widely used as a first line therapy in the management of breast cancer. Early clinical results indicated that the threshold of consistent therapeutic activity lay between 10 and 20 mg daily. Ward (1973), in a small randomised comparison of 10 mg bd and 20 mg bd, reported a greater tumour response rate at the higher dose, although the difference was not statistically significant. The only other direct comparison of two dosages was a non-randomised study (Lerner *et al.*, 1976) in which the results were considered inconclusive. A review of 19 major clinical trials (Mouridsen *et al.*, 1978) suggested that a dose of 40 mg daily was associated with a higher overall response than 20 mg daily (39% *versus* 28%) but this conclusion needs confirming in a prospective randomised trial.

Recently a method for analysing concentrations of tamoxifen in serum has become available (Adam *et al.*, 1980a). No correlation between serum concentrations and clinical response was found in 39 patients but it was recommended that a further study in a larger number of patients was required (Patterson *et al.*, 1980).

The purpose of this trial was to compare tumour response rate and duration between the two most commonly used dosage regimens of tamoxifen, viz 10 mg bd and 20 mg bd, and to attempt to correlate clinical response with serum tamoxifen level in a large number of patients.

Patients and methods

The trial was carried out at two separate centres (Cambridge and Southampton).

Postmenopausal women with primary inoperable, locally recurrent or metastatic breast cancer with measurable or evaluable disease were assessed. Patients previously treated with tamoxifen and those receiving other endocrine therapies within the previous 6-weeks were excluded. During the trial, concomitant anticancer medication was not permitted, with the exception of palliative radiotherapy for painful bone metastases, which were then excluded as evaluable lesions.

Patients were allocated, double blind, to receive tamoxifen either 10 mg or 20 mg twice daily in the form of matching tablets by the hospital pharmacist using a computer-generated randomisation code. Because the supply of matching 20 mg tablets was limited, only 4 months' treatment was provided for each patient. After 4 months' therapy the code for individual patients was broken and further tamoxifen was prescribed using conventional sales material ("Nolvadex" 10 mg).

General clinical status, side effects and soft tissue disease were evaluated monthly for the first 4 months. Bone and lung lesions were assessed radiologically on entry and at 3 months. Hepatic involvement was judged clinically by measuring liver size below the costal margin. Tumour response to therapy was assessed according to the U.I.C.C. criteria (Hayward *et al.*, 1977, 1978). Briefly, the four response categories were defined as follows:

Complete response (CR) disappearance of all known lesions, determined by two observations not

*"Nolvadex" is a Trade Mark, the property of Imperial Chemical Industries PLC.

Correspondence: D.G. Bratherton.

Received 24 April 1984; accepted 22 May 1984.

less than 4 weeks apart. In the case of lytic bone metastases, these must be shown radiologically to have calcified.

Partial response (PR) Fifty percent decrease in measurable lesions and objective improvement in evaluable but non-measurable lesions, determined by two observations not less than 4 weeks apart. No new lesions should have appeared. It is not necessary for every lesion to have regressed to qualify for partial response, but no lesion should have progressed.

No change (NC) lesions unchanged (i.e. 50% decrease or 25% increase in the size of measurable lesions). If non-measurable but evaluable lesions represent the bulk of disease and these clearly do not respond even though measurable lesions have improved, then this is considered as no change and not partial response.

Progressive disease (PD) Twenty-five percent increase in the size of any lesion or the appearance of new lesions.

Patients withdrawing from the trial for any reason during the first 4 weeks were considered to be "treatment failures".

Initial response was assessed at 3 months and confirmed at 4 months. Tamoxifen treatment was continued in patients achieving CR or PR or NC with stable/improving performance status at the discretion of the physician. Tamoxifen was discontinued after 3 months if patients showed PD or NC with deteriorating performance status and was also withdrawn at any time when rapid disease progression or intolerable side effects occurred.

The duration of response was taken as the length of time between the start of tamoxifen therapy and documentation of progressive disease, the introduction of additional or alternative anticancer medication or the withdrawal of tamoxifen.

Tumour response data were audited by exchange of record forms between the principal investigators of the two centres.

The proportion of responders has been analysed using logistic regression. The terms fitted were dose, age, disease-free interval, presence/absence of primary tumour and dominant site. Duration of response has been compared between the two dose groups using the logrank test (Peto *et al.*, 1977).

Where possible two 10 ml samples of blood were taken from each patient at least one month apart between the 8th and 16th week of treatment by which time steady state kinetics were assumed to have been reached (Patterson *et al.*, 1980). Serum was analysed for tamoxifen and desmethyl metabolite concentrations using the method described by Adam *et al.* (1980b). Results were not

disclosed to the clinician until the trial was complete.

Results

Of 263 patients recruited, 26 (15 on 10 mg bd; 11 on 20 mg bd) were excluded from the analysis on the grounds of protocol ineligibility or inadequacy of data recording. A further 16 (11 on 10 mg bd; 5 on 20 mg bd) were withdrawn from the trial within four weeks of starting treatment for the reasons shown in Table I and these were classified as treatment failures.

Distribution of the 237 assessable patients by dose according to baseline characteristics is shown in Table II. The two groups were well matched except for a preponderance of bone-dominant disease (25 *versus* 14) and correspondingly fewer patients with soft tissue dominant disease (70 *versus* 75) in the higher dose group. However the logistic regression method of analysis used takes into account any imbalance in prognostic variables (Armitage & Gehan, 1974). Most patients (96%) had not received any previous systemic additive treatment for their disease.

With 237 evaluable patients there is an 80% chance of obtaining a statistically significant result at the 5% level (two-tailed) if the true difference in response rates was at least 18% (30–48%).

Table I Reasons for withdrawal from trial within 4 weeks

	No. of patients	
	10 mg bd	20 mg bd
Death	4	1
Withdrawn due to side effects	1	1
Defaulted	4	3
Rapid deterioration	1	—
Other	1	—
	11	5

Tumour response rates

Objective tumour response rates (CR+PR) are shown in Table III. Thirty-four percent (39/116) of patients in the 10 mg bd group achieved more than 50% tumour regression compared with 31% (37/121) in the 20 mg bd group. Inclusion of patients achieving disease stabilisation (NC) gives response rates of 50% (58/116) and 57% (69/121) respectively. None of these differences is statistically significant.

Table II Patient demography

	<i>Dose of tamoxifen</i>	
	<i>10 mg bd</i>	<i>20 mg bd</i>
No. of patients	116	121
Age (yr)		
Mean	69.3	67.4
Range	45-91	38-89
Disease free interval:		
1 yr	62	63
1-5 yrs	38	40
> 5 yrs	15	17
Not documented	1	1
Previous treatment:		
None	41	42
Surgery	57	69
Radiotherapy	56	45
Other	4	5
Primary tumour:		
Present	54	50
Absent	61	70
Not documented	1	1
Dominant site:		
Soft tissue	75	70
Bone	14	25
Visceral	26	25
Not documented	1	1

Table III Tumour response to tamoxifen by dose level

<i>Tumour response</i>	<i>Tamoxifen</i>	
	<i>10 mg bd</i>	<i>20 mg bd</i>
CR	14	9
PR	25	28
NC	19	32
PD	47	47
Failure	11	5
CR + PR	39/116 (33.6%)	37/121 (30.6%)
CR + PR + NC	58/116 (50.0%)	69/121 (57.0%)

With respect to prognostic variables, a significant correlation between both the dominant site of disease and presence/absence of primary tumour and tumour response to therapy was found. In the case of dominant site (Table IV), the response rate was significantly higher for soft tissue dominant disease than either bone dominant ($P=0.037$) or visceral dominant ($P=0.003$) disease. In the case of presence/absence of primary tumour (Table V), those patients with a primary tumour irrespective of other lesions showed a statistically significantly

Table IV Tumour response to tamoxifen by dominant site regardless of dose

<i>Tumour response</i>	<i>Dominant site</i>		
	<i>Soft tissue</i>	<i>Bone</i>	<i>Visceral</i>
CR	20	1	2
PR	38	8	7
NC	34	9	8
PD	50	18	26
Failures	3	3	8
CR + PR	58/145 (40.0%)	9/39 (23.1%)	9/51 (17.6%)

Table V Tumour response to tamoxifen by primary tumour regardless of dose

<i>Tumour response</i>	<i>Primary tumour</i>	
	<i>Present</i>	<i>Absent</i>
CR	2	21
PR	24	29
NC	28	23
PD	44	50
Failures	6	8
CR + PR	26/104 (25.0%)	50/131 (38.2%)

lower ($P=0.035$) response rate than those without a primary tumour.

Response with respect to age and disease free interval (DFI) are shown in Tables VI and VII. The differences in response rates between the various strata did not achieve statistical significance, although some trend towards an increasing response rate with age up to 80 years and length of DFI is evident.

Table VI Tumour response to tamoxifen by age regardless of dose

<i>Tumour response</i>	<i>Age range (years)</i>			
	<i>< 60</i>	<i>60-69</i>	<i>70-79</i>	<i>≥ 80</i>
CR	4	5	11	3
PR	8	18	19	8
NC	8	15	14	14
PD	25	35	27	7
Failures	6	2	3	2
CR + PR	12/51 (23.5%)	23/75 (30.7%)	30/74 (40.5%)	11/34 (32.4%)

Table VII Tumour response by disease free interval regardless of dose

Tumour response	Disease free interval (y)		
	<1 y	1-5 y	>5 y
CR	4	13	6
PR	30	17	6
NC	33	10	8
PD	52	32	10
Failures	6	6	2
CR + PR	34/125 (27.2%)	30/78 (38.5%)	12/32 (37.5%)

Duration of response

The median durations of objective response for the 10 mg bd and 20 mg bd groups were 18 and 12 months respectively. This difference is not statistically significant ($P < 0.10$). At the time when data was analysed 20 patients (51%) in the 10 mg bd and 14 (38%) in the 20 mg bd group were still in remission.

Both groups of patients were followed up identically, to either the date of withdrawal from the trial or if response was continuing, to the date of analysis. In both groups, the median duration of follow-up was 4 months.

Improvement of response category after the trial

Although tumour response to treatment was only assessed double-blind for four months and response rates quoted above refer to the situation during that period, 10 patients subsequently showed improvement in response category and the majority of these eventually achieved complete remission of their disease (Table VIII). One patient with

Table VIII Improvement of tumour response category after the initial four month treatment period

Dosage group	Initial classification (4 month)	Best response
10 mg bd	PD*	→ CR
	NC	→ PR
	PR	→ CR
	PR	→ CR
	PD	→ PR
	PR	→ CR
	PR	→ CR
20 mg bd	NC	→ PR
	NC	→ CR
	PR	→ CR

*Dose changed to 20 mg bd.

progressive disease after 4 months on the lower dose became a complete responder when the dose was increased to 20 mg bd.

Adverse reactions

A total of 31 adverse effects were reported by 24 (9%) of the patients entered but there was no consistent indication that these were dose-related (Table IX). Three patients (1%) were withdrawn due to treatment intolerance: paroxysmal nocturnal dyspnoea (1 patient at 20 mg bd), vaginal discharge (1 patient at 20 mg bd), oedema (1 patient at 10 mg bd). Against the spontaneous background incidence of symptoms in women with advanced malignancy and in the absence of a control group however, it is impossible to ascertain what proportion of these symptoms was definitely drug-related.

Table IX Side effects associated with tamoxifen therapy

Side effect	Number of patients	
	10 mg bd	20 mg bd
Nausea	3	3
Vomiting	1	0
Hot flushes	1	1
Vaginal discharge	1	2
Vaginal bleeding	0	1
Pruritis	0	1
Cardiac failure	2	2
Dyspnoea	1	0
Anorexia	0	1
Abdominal pain	0	1
Constipation/diarrhoea	2	0
Dysphagia	0	1
Tiredness	0	4
Depression	0	1
Vertigo	1	0
Bone pain	0	1
Total	12	19

Serum tamoxifen analysis

Serum samples for drug analysis were obtained from 152 subjects (64% of evaluable cases). In 59 patients only a single sample was available. In the remaining 93 cases the mean value of the two determinations was used. Concentrations of tamoxifen and desmethyltamoxifen were within 20% of each other in 60 and 58 instances respectively and in 45 instances for both compounds. Hence in this subgroup steady state kinetics were unequivocally demonstrated but attempts to correlate the steady state serum

concentrations with clinical results were unsuccessful. The ratio of metabolite to parent compound was reasonably constant thus allowing the ratio to be used as an indication of patient compliance; poor compliance would result in higher metabolite concentrations because of the longer half life of the latter compound leading to an increased metabolite/parent compound ratio.

Table X shows the results of analysis of variance of serum concentrations allowing for dose and response (CR+PR) and the interaction between these parameters. There were no significant differences between responders and non-responders either within a dose group or on combining dose groups. The mean serum concentrations of 159 ng ml^{-1} and 273 ng ml^{-1} for 10 and 20 mg bd respectively were markedly different ($P < 0.0001$). Figure 1 shows the scattergram of serum concentrations of tamoxifen in the two dose groups.

In the group in which steady state kinetics were proven, the mean ratio of metabolite to unchanged drug concentration was 1.79 ± 0.01 ($n=25$) for the 10 mg bd group and 1.87 ± 0.08 ($n=20$) for the 20 mg bd dose group. These were not significantly different. This suggests there was no difference in compliance between the two groups of patients.

Table X Serum tamoxifen concentrations for all patients

Response	Dose of tamoxifen		
	10 mg bd	20 mg bd	Overall ^c
Responders	Mean 158.6	289.6	224.1 ^a
	s.e. 11.1	20.2	11.4
	n 36	28	64
Non-responders	Mean 160.0	256.8	208.4 ^a
	s.e. 11.3	15.7	9.6
	n 41	47	88
Overall ^b	Mean 159.3 ^a	273.2 ^a	
	s.e. 10.3	10.8	
	n 77	75	

^aThese means have been adjusted to allow for the unequal numbers in the cells.

^bOverall difference between dose levels significant ($P < 0.0001$).

^cOverall difference between responders and non-responders not significant ($P > 0.05$).

Discussion

The results of this trial involving 237 evaluable postmenopausal patients with advanced breast cancer have failed to detect a significant therapeutic




Figure 1

advantage for a tamoxifen dose of 20 mg bd compared with 10 mg bd. In a previous smaller comparison between 20 and 40 mg daily (Ortiz de Taranco *et al.*, 1979), the objective response rates were also not significantly different. However, consideration of the NC group brought the total response rates (CR+PR+NC) to 51% for 20 mg daily and 79% for 40 mg daily thus demonstrating a statistically significant advantage for the higher dose. The corresponding overall response rates in our trial were 50% and 57% which concurs with

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.